Similar findings were recently reported by Sánchez-Paulete et al., who demonstrated that Flt3L-mobilized Batf3-dependent DC activated by poly-ICLC synergized with anti-CD137 and anti-PD-1 monoclonal antibody therapy to promote Ag-specific CD8+ T cell cross-priming and tumor control (132). Here, FLT3LG is linked to neoplasm.